Paul Jeng
Stock Analyst at Guggenheim
(2.87)
# 1,601
Out of 5,124 analysts
6
Total ratings
80%
Success rate
28.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Initiates: Buy | $9 | $1.82 | +394.51% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $9.60 | +97.92% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $32.76 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $1.65 | +203.03% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $36.31 | +37.70% | 1 | Sep 18, 2025 |
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $1.82
Upside: +394.51%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $9.60
Upside: +97.92%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $32.76
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $1.65
Upside: +203.03%
IDEAYA Biosciences
Sep 18, 2025
Initiates: Buy
Price Target: $50
Current: $36.31
Upside: +37.70%